These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28418189)

  • 21. Cerebral autoregulation dynamics in acute ischemic stroke after rtPA thrombolysis.
    Reinhard M; Wihler C; Roth M; Harloff A; Niesen WD; Timmer J; Weiller C; Hetzel A
    Cerebrovasc Dis; 2008; 26(2):147-55. PubMed ID: 18560218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proportion of single-chain recombinant tissue plasminogen activator and outcome after stroke.
    Leys D; Hommet Y; Jacquet C; Moulin S; Sibon I; Mas JL; Moulin T; Giroud M; Sagnier S; Cordonnier C; Medeiros de Bustos E; Turc G; Ronzière T; Bejot Y; Detante O; Ouk T; Mendyk AM; Favrole P; Zuber M; Triquenot-Bagan A; Ozkul-Wermester O; Montoro FM; Lamy C; Faivre A; Lebouvier L; Potey C; Poli M; Hénon H; Renou P; Dequatre-Ponchelle N; Bodenant M; Debruxelles S; Rossi C; Bordet R; Vivien D;
    Neurology; 2016 Dec; 87(23):2416-2426. PubMed ID: 27815401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute stroke management in the elderly.
    Zeevi N; Chhabra J; Silverman IE; Lee NS; McCullough LD
    Cerebrovasc Dis; 2007; 23(4):304-8. PubMed ID: 17199089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.
    Wahlgren N; Ahmed N; Dávalos A; Hacke W; Millán M; Muir K; Roine RO; Toni D; Lees KR;
    Lancet; 2008 Oct; 372(9646):1303-9. PubMed ID: 18790527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous alteplase for stroke in those older than 80 years old.
    Ford GA; Ahmed N; Azevedo E; Grond M; Larrue V; Lindsberg PJ; Toni D; Wahlgren N
    Stroke; 2010 Nov; 41(11):2568-74. PubMed ID: 20930163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
    Anderson CS; Robinson T; Lindley RI; Arima H; Lavados PM; Lee TH; Broderick JP; Chen X; Chen G; Sharma VK; Kim JS; Thang NH; Cao Y; Parsons MW; Levi C; Huang Y; Olavarría VV; Demchuk AM; Bath PM; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Ricci S; Roffe C; Pandian J; Billot L; Woodward M; Li Q; Wang X; Wang J; Chalmers J;
    N Engl J Med; 2016 Jun; 374(24):2313-23. PubMed ID: 27161018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis.
    Dorado L; Millán M; de la Ossa NP; Guerrero C; Gomis M; López-Cancio E; Ricciardi AC; Dávalos A
    Eur J Neurol; 2010 Feb; 17(2):301-6. PubMed ID: 19912320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: evidence from the Japan Alteplase Clinical Trial (J-ACT).
    Mori E; Minematsu K; Nakagawara J; Yamaguchi T;
    J Stroke Cerebrovasc Dis; 2011 Nov; 20(6):517-22. PubMed ID: 20719535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke.
    Barreto AD; Fanale CV; Alexandrov AV; Gaffney KC; Vahidy FS; Nguyen CB; Sarraj A; Rahbar M; Grotta JC; Savitz SI;
    Ann Neurol; 2016 Aug; 80(2):211-8. PubMed ID: 27273860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining mild stroke: outcomes analysis of treated and untreated mild stroke patients.
    Spokoyny I; Raman R; Ernstrom K; Khatri P; Meyer DM; Hemmen TM; Meyer BC
    J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1276-81. PubMed ID: 25906938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of early poststroke seizures during reperfusion therapies in patients with acute ischemic stroke: An observational prospective study: (TESI study: "Trombolisi/Trombectomia e crisi Epilettiche precoci nello Stroke Ischemico").
    Belcastro V; Brigo F; Ferlazzo E; Gasparini S; Mastroianni G; Cianci V; Lattanzi S; Silvestrini M; Versino M; Banfi P; Carimati F; Grampa G; Lochner P; Gigli GL; Bax F; Merlino G; Valente M; Vidale S; Aguglia U
    Epilepsy Behav; 2020 Mar; 104(Pt B):106476. PubMed ID: 31431399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Readministration of intravenous alteplase in acute ischemic stroke patients: case series and systematic review.
    Qureshi AI; Malik AA; Freese M; Thompson MJ; Khan AA; Suri MF
    Am J Emerg Med; 2015 Feb; 33(2):307.e1-4. PubMed ID: 25190550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients.
    Li W; Lin L; Zhang M; Wu Y; Liu C; Li X; Huang S; Liang C; Wang Y; Chen J; Feng W
    Stroke; 2016 Oct; 47(10):2649-51. PubMed ID: 27608821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posterior circulation stroke is associated with prolonged door-to-needle time.
    Sarraj A; Medrek S; Albright K; Martin-Schild S; Bibars W; Vahidy F; Grotta JC; Savitz SI
    Int J Stroke; 2015 Jul; 10(5):672-8. PubMed ID: 23521891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
    Kumar G; Uhrig D; Fowler S; DeLaney MC; Alexandrov AV
    CNS Drugs; 2015 Aug; 29(8):659-67. PubMed ID: 26251162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does the application of X-ray contrast agents impair the clinical effect of intravenous recombinant tissue-type plasminogen activator in acute ischemic stroke patients?
    Dzialowski I; Puetz V; Buchan AM; Demchuk AM; Hill MD;
    Stroke; 2012 Jun; 43(6):1567-71. PubMed ID: 22496336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.
    Davis SM; Donnan GA; Parsons MW; Levi C; Butcher KS; Peeters A; Barber PA; Bladin C; De Silva DA; Byrnes G; Chalk JB; Fink JN; Kimber TE; Schultz D; Hand PJ; Frayne J; Hankey G; Muir K; Gerraty R; Tress BM; Desmond PM;
    Lancet Neurol; 2008 Apr; 7(4):299-309. PubMed ID: 18296121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of daytime, weekday and year of admission on outcome in acute ischaemic stroke patients treated with thrombolytic therapy.
    Jauss M; Schütz HJ; Tanislav C; Misselwitz B; Rosenow F
    Eur J Neurol; 2010 Apr; 17(4):555-61. PubMed ID: 20218973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.